Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: May 22, 2013
Last updated: May 12, 2017
Last verified: May 2017
A study to evaluate the efficacy, immunogenicity, and tolerability of V501 (quadrivalent Human Papilloma Virus [HPV] [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine, GARDASIL™) in healthy, 16- to 26-year old Japanese males. The hypotheses tested are: 1) V501 reduces the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection compared with placebo, and 2) V501 reduces the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, condyloma acuminata, penile/perianal/perineal intraepithelial neoplasia, or penile, perianal, or perineal cancer compared with placebo.

Condition Intervention Phase
Anogenital Human Papilloma Virus Infection
Condyloma Acuminata
Biological: V501
Biological: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator, Outcomes Assessor
Primary Purpose: Prevention
Official Title: A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Combined Incidence of HPV 6-, 11-, 16-, or 18-Related Persistent Infection [ Time Frame: Up to 36 months ]
  • Percentage of Participants with an Adverse Event (AE) [ Time Frame: Up to 14 days after any vaccination ]
  • Percentage of Participants with Vaccine-Related Serious Adverse Events (SAEs) [ Time Frame: Up to 36 Months ]

Secondary Outcome Measures:
  • Combined Incidence of HPV 6-, 11-, 16-, or 18-Related Persistent Infection, Condyloma Acuminata, Penile/Perianal/Perineal Intraepithelial Neoplasia, or Penile, Perianal, or Perineal Cancer [ Time Frame: Up to 36 months ]

Estimated Enrollment: 1100
Actual Study Start Date: June 27, 2013
Estimated Study Completion Date: September 26, 2017
Estimated Primary Completion Date: September 26, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: V501
V501: 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
Biological: V501
Other Names:
  • Quadrivalent HPV (Type 6, 11, 16 and 18) L1 Virus-Like Particle vaccine
Placebo Comparator: Placebo
Placebo to match V501: 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
Biological: Placebo


Ages Eligible for Study:   16 Years to 26 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Japanese
  • No clinical evidence of gross genital lesion suggesting sexually-transmitted disease and no clinically present external genital warts
  • Other inclusion criteria will be discussed with the investigator during screening

Exclusion Criteria:

  • History of known prior vaccination with an HPV vaccine or plans to receive one outside the study
  • History of external genital warts
  • History of severe allergic reaction that required medical intervention
  • Received immune globulin or blood-derived products in the past 6 months or plan to receive any before Month 7 of the study
  • History of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, Human Immunodeficiency Virus (HIV), lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition
  • Received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids and certain regimens of systemic corticosteroids
  • Known thrombocytopenia or coagulation disorder that would contraindicate intramuscular injections
  • Ongoing alcohol or drug abuse within the past 12 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT01862874     History of Changes
Other Study ID Numbers: V501-122
132237 ( Registry Identifier: JAPIC-CTI )
Study First Received: May 22, 2013
Last Updated: May 12, 2017

Additional relevant MeSH terms:
Virus Diseases
Papillomavirus Infections
Neoplasms, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
DNA Virus Infections
Tumor Virus Infections processed this record on May 25, 2017